A new online community for patients with Parkinson's disease, their carers and healthcare professionals has been launched by Britannia Pharmaceuticals.

The UK firm, which is part of the Stada group, will use The Parkinson Hub to share news and best practice about Parkinson's disease, with an emphasis on the disease's mid- to late-stages.

The community provides an overview of the disease, including the nature of the condition and information on available treatment options.

Britannia's own product in the area is its apomorphine treatment, which is indicated for motor fluctuations (the so-called “on-off” phenomena) in Parkinson's patients whose disease is not sufficiently controlled by oral anti-Parkinson medications.

It is marketed as APO-go in the UK and Europe, APOKYN in the United States and Japan, APOKYN in France and Apomine in Australia.

The new community also highlights inspirational examples of celebrities, such as Michael J Fox, and 'everyday heroes' who are “living their lives to the full” despite suffering from Parkinson's.

Britannia is accompanying the community's launch with its new PD Quality of Life resource, which enables people with Parkinson's to identify and understand those areas in their life most impacted by their condition.

Britannia said the resource, which currently available in English, Spanish and German, would empower patients “to have a more informed discussion about their well-being and unique needs with their healthcare professionals and care teams”.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more